Header links
Intranet
Donate now
image/svg+xml Map
Contact us

Juan Manuel Pericàs Pulido

Juan Manuel Pericàs Pulido

Institutions of which they are part

Main researcher
Liver Diseases
Vall Hebron Institut de Recerca
Juan Manuel Pericàs Pulido

Juan Manuel Pericàs Pulido

Juan Manuel Pericàs Pulido

Institutions of which they are part

Main researcher
Liver Diseases
Vall Hebron Institut de Recerca

Research lines

Metabolisme hepàtic i infeccions (LivMI)

Epidemiologia del fetge gras no alcohòlic, biomarcadors i nous tractament

Infeccions malaltia hepàtica avançada

IP: Juan Manuel Pericàs Pulido

Projects

ARTEMIs: AcceleRating the Translation of virtual twins towards a pErsonalised Management of fatty lIver patients

IP: José Raul Herance Camacho
Collaborators: Beatriz Minguez Rosique, Clara Ramírez Serra, Cristina Gamez Cenzano, Juan Manuel Pericàs Pulido, Nuria Roson Gradaille, Andreea Ciudin Mihai, Alberto Roque Pérez, Queralt Martin Saladich, Maria Nazarena Pizzi, Ramón Vilallonga Puy
Funding agency: EUROPEAN COMMISSION
Funding: 724000
Reference: ARTEMIS_HE-HLTH2023
Duration: 01/01/2024 - 31/12/2027

Patient-derived liver biopsy-organoids for personalized medicine in NAFLD (non-alcoholic fatty liver disease): towards real time assessment of drug response (B-Org)

IP: Juan Manuel Pericàs Pulido
Collaborators: -
Funding agency: Fundació Institut Bioenginyeria de Catalunya
Funding: 0.01
Reference: IBEC/2022/PERICAS
Duration: 02/01/2023 - 31/12/2024

Proyecto de formación integral en enfermedad hepática crónica avanzada

IP: Juan Manuel Pericàs Pulido
Collaborators: Miriam Izquierdo Sans
Funding agency: Instituto de Salud Carlos III
Funding: 65000
Reference: CM23/00251
Duration: 02/01/2024 - 01/01/2026

Caracterización de las claves fisiopatológicas y fenotipos de la enfermedad del hígado graso metabólica con ingesta moderada de alcohol para identificar nuevas terapias (ReLiveR).

IP: Meritxell Ventura Cots
Collaborators: Immaculada Raurell Saborit, Juan Manuel Pericàs Pulido, Laura Puente Ramo, Ares Aurora Villagrasa Vilella, Juan Bañares Sanchez, Maria de la Serra Cusidó Sabidó, Maria Martínez Gómez
Funding agency: Instituto de Salud Carlos III
Funding: 183920
Reference: PI22/01770
Duration: 01/01/2023 - 31/12/2025

Related news

Dr. Raul Herance

We develop a method to diagnose fatty liver in a quantitative and non-invasive way

Using computed tomography (CT), with or without contrast, it is possible to perform an accurate and safe detection of the disease without the need for biopsies and avoiding the limitations of other non-invasive diagnostic tools.

Pacient d'un assaig clínic a la consulta

VHIR exceeds 700 active clinical trials to achieve new therapies for patients

On World Clinical Trials Day, we highlight some of the studies we have participated in that confirm the efficacy of new drugs, allowing their approval by regulatory agencies.

Grup de Malalties Hepàtiques del VHIR

A clinical trial has led to approval of the first drug for advanced fatty liver disease

Preliminary study results confirm that the drug resmetirom reduces the presence of fat, inflammation, cell damage and fibrosis in the liver.

See more

Related professionals

Mercè Roca Lòpez

Mercè Roca Lòpez

Administration and Management
Read more
Remedios Rios Barrera

Remedios Rios Barrera

Senior researcher
Cardiovascular Diseases
Read more
Yassin Belahnech Pujol

Yassin Belahnech Pujol

Main researcher
Cardiovascular Diseases
Read more
Hakima Ouaarab Essadek

Hakima Ouaarab Essadek

Infectious Diseases
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.